NasdaqCM - Nasdaq Real Time Price USD

Motus GI Holdings, Inc. (MOTS)

0.1735

0.0000

(0.00%)

At close: April 15 at 4:00 PM EDT

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FO

GlobeNewswire last month
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock for gross proceeds to the Comp

GlobeNewswire last month
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce further strengthening our IP portfolio in the U.S. This latest patent c

GlobeNewswire last month
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on January 2

GlobeNewswire 2 months ago
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation

FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, “An intraprocedural bowel cleansing system for difficult-to-prepare patients—A multicenter prospective feasibility study,” in the peer-reviewed journal, Unite

GlobeNewswire 2 months ago
Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering

FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the pricing of a public offering of 3,333,334 shares of common stock (or pre-funded warrants in lieu thereof), Series A common warrants to purchase up to 3,333,334 shares of common stock, and Series B common warrants to purchase up to 3,333,334 shares of common stock,

GlobeNewswire 3 months ago
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update

First case performed using the new FDA cleared Pure-Vu® EVS Gastro system, and expect to initiate broader market introductions by the end of 2023Pure-Vu EVS Gastro addresses the Upper GI market, an area of high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. according to iData Research Inc.The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and

GlobeNewswire 5 months ago
Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro

Pure-Vu EVS irrigation jets Caption: Pure-Vu EVS irrigation jets washing a biopsy site in the Upper GI tract - - -The upper GI procedure was performed by Dr. Brian Hanson, gastroenterologist and Assistant Professor, Medicine, at the University of Minnesota- - -Pure-Vu EVS Gastro addresses the Upper GI market, an area of high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. according to iData Research Inc. FORT LAUDERDALE, Fla., Nov. 10, 2023 (GLO

GlobeNewswire 5 months ago
Motus GI Announces 1-for-15 Reverse Stock Split

FORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it will effect a 1-for-15 reverse stock split of its outstanding common stock. The Company’s common stock will begin trading on a split-adjusted basis at the opening of the market on Thursday, November 2, 2023. The Company’s common stock will continue to trade on t

GlobeNewswire 5 months ago
Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon

– Clearance opens up the potential breakthrough opportunity in the Upper GI market, an area of high unmet clinical need – – Technological advancements featured in new generation of the Pure-Vu platform, enhance the performance of the system, improve the ease of use and minimizes the need for onsite support to new accounts – – Expect to initiate market introduction of the new Pure-Vu EVS platform by year-end for both the Upper GI and Colon indications – FORT LAUDERDALE, Fla., Oct. 24, 2023 (GLOBE

GlobeNewswire 5 months ago
Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon

– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt – – Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and minimizes the need for onsite support to new accounts – FORT LAUDERDALE, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it has

GlobeNewswire 6 months ago
Motus GI Amends Royalty Agreement

– Amended agreement eliminates approximately $1.0M in contingent royalty obligations from balance sheet – – Canceled royalty rights in exchange for common stock expected to improve Company’s stockholder equity, and simplify ongoing exploration of strategic and financing alternatives to maximize stockholder value – FORT LAUDERDALE, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endos

GlobeNewswire 7 months ago
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

-- David Hochman and Darren Sherman resign from Motus Board of Directors to focus on their executive obligations --FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors (the “Board”). Mr. Durbin has more than 25 years of executive leadership, finance and clini

GlobeNewswire 7 months ago
Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference

FORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that Mark Pomeranz, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. H.C. Wainwright 25th Annual Global Investment ConferencePresentation Date:Monday, September 11, 2023 at 7:00 AM ETMeetings:Managemen

GlobeNewswire 7 months ago
Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

On track to submit planned special 510(k) for Pure-Vu Gen 4 Gastro and Colon to the FDA in Q4 2023;Received system wide approval in the Banner Medical Hospital Network and installed the first system at the Banner Dessert Medical Center in Mesa, Ariz.The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Motus

GlobeNewswire 8 months ago
Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System

FORT LAUDERDALE, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has received approval from the Israeli Ministry of Health, Medical Device Division (known as "AMAR") to initiate commercial sales of the Pure-Vu® EVS System in Israel. “We are pleased to secure regulatory clearance for the Pure-Vu EVS System in Israel, which is

GlobeNewswire 8 months ago
Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center

Implementation of the Pure-Vu system designed to improve efficiencies and outcomes of GI endoscopy proceduresInitial agreement expected to provide an easier sales process to the other more than 30 medical centers within the Banner Medical network FORT LAUDERDALE, Fla., July 20, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that Banner Desert Med

GlobeNewswire 8 months ago
Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center

Pure-Vu system featured in live case during an underwater large polyp resection in the colonOver 1,000 physicians registered for IECED Live Endoscopy Course from across Latin AmericaPure-Vu Gen 4 Gastro and Colon on track for FDA submission in Q4 2023 FORT LAUDERDALE, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the Pure-Vu

GlobeNewswire 10 months ago
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE

GlobeNewswire 10 months ago
Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer

Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers, including seeking key FDA approvals and pursuit of strategic partnerships to accelerate commercialization FORT LAUDERDALE, Fla., June 05, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced the promotion of its current Vice Presid

GlobeNewswire 10 months ago

Performance Overview

Return	MOTS	S&P 500
YTD	-86.39%	+4.14%
1-Year	-98.73%	+19.55%
3-Year	-99.94%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Motus GI Holdings, Inc. (MOTS)

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering

Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro

Motus GI Announces 1-for-15 Reverse Stock Split

Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon

Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon

Motus GI Amends Royalty Agreement

Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System

Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer

Performance Overview